Gastrointestinal
ulcers and
bleeding are serious complications of nonsteroidal anti-inflammatory drug (
NSAID) use. Although administration of
antibiotics and
Toll-like receptor 4 knockdown mitigate
NSAID-induced enteropathy, the molecular mechanism of these effects is poorly understood. Intestinal hyperpermeability is speculated to trigger the initial damage due to
NSAID use. Transient receptor potential vanilloid 4 (TRPV4) is a nonselective
cation channel expressed throughout the gastrointestinal tract epithelium that is activated by temperature, extension, and chemicals such as 5,6-epoxyeicosatrienoic
acid (5,6-EET). The aim of this study was to investigate the possible role of TRPV4 in
NSAID-induced intestinal damage. TRPV4
mRNA and
protein expression was confirmed by RT-PCR and immunochemistry, respectively, in mouse and human tissues while TRPV4 channel activity of the intestinal cell line IEC-6 was assessed by Ca(2+)-imaging analysis. TRPV4 activators or the
NSAID indomethacin significantly decreased transepithelial resistance (TER) in IEC-6 cells, and
indomethacin-induced TER decreases were inhibited by specific TRPV4 inhibitors or
small-interfering RNA TRPV4 knockdown, as well as by the epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide, which decreased
5,6-EET levels. In TRPV4 knockout mice,
indomethacin-induced intestinal damage was significantly reduced compared with WT mice. Taken together, these results show that TRPV4 activation in the intestinal epithelium caused epithelial hyperpermeability in response to
NSAID-induced
arachidonic acid metabolites and contributed to
NSAID-induced intestinal damage. Thus, TRPV4 could be a promising new therapeutic target for the prevention of
NSAID-induced intestinal damage.